ClinicalTrials.gg
Status unknownNCT03341572Updated Nov 14, 2017

The Effect of Positive End Expiratory Pressure on Central Venous Pressure Among Patients With Different Lung Compliance

An interventional study of 5,10 and 15cmH2O positive end expiratory pressure in Sepsis, ARDS and Traumatic Brain Injury, sponsored by Jingyuan,Xu. Status unknown at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-11-14.

Sponsored by Jingyuan,Xu · Not applicable, Interventional, and Supportive care

The sponsor has not verified this record recently (last verified Nov 2017), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

To observe the effect of PEEP on CVP among patients with different respiratory compliance

Read the detailed description

30 patients with mechanical ventilation and inserted central venous line will be entered. After gathering demographic data, patients undergone 5,10 and 15cmH2O PEEPs and the respective CVPs of the mentioned points will be recorded. According to the change of CVP, the patients will be divided into high response group and low response group, then comparing the lung compliance and thorax elastic resistance differences between the two groups.

02

Conditions studied

  • Sepsis
  • ARDS
  • Traumatic Brain Injury
03

In context

Sepsis

2,416 studies on the registry are indexed under Sepsis; 541 are open to participants now.

This study's planned enrollment of 30 is below the median of 102 across 1,165 interventional studies indexed under Sepsis.

Browse Sepsis studies →

Lead sponsor

Jingyuan,Xu is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with mechanical ventilation and inserted central venous line

Exclusion criteria

Exclusion Criteria:

  1. The age is less than 18 years old or more than 80 years old;
  2. Pregnant and lying-in woman;
  3. Patients undergoing fluid resuscitation and the speed is more than 200ml/h;
  4. Patients with norepinephrine dose are greater than 15 micro per minute;
  5. Patients with pericarditis、pulmonary heart disease、right heart failure、atrial fibrillation;
  6. Patients with (endogenous PEEP is more than 2cmH2O)、tension pneumonthorax、acute episode asthma
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    high response group

    patients undergo 5,10 and 15cmH2O positive end expiratory pressure ,the change of central venous pressure is more than 2.5cmH2O

    Other: 5,10 and 15cmH2O positive end expiratory pressure

  • Placebo comparator
    low response group

    the change of CVP is less than 2.5cmH2O

    Other: 5,10 and 15cmH2O positive end expiratory pressure

Interventions

  • Other5,10 and 15cmH2O positive end expiratory pressure

    every patients undergo 5,10 and 15cmH2O positive end expiratory pressure,and observe the central venous pressure of the mentioned points

06

What researchers measure

Primary outcomes

  1. CVP

    Measure the central venous pressure of the three level PEEPs of 5,10 and 15cmH2O.

    Time frame: half an hour

07

Study locations

1 of 1 sites recruiting
  • Zhongda Hospital
    Nanjing, Jiangsu 210000, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03341572
Lead sponsor
Jingyuan,Xu
Responsible party
Jingyuan,Xu (Attending doctor, Southeast University, China) — Sponsor-investigator
First posted
Nov 14, 2017
Start date
Nov 13, 2017 (estimated)
Primary completion
Dec 30, 2017 (estimated)
Completion
Dec 30, 2017 (estimated)
Last update
Nov 14, 2017

Study contacts

chenglong liang, master
Contact
15261893562@163.com
15261893562
yi yang, doctor
Contact
yiyiyang2004@163.com
+8602583262550
yi yang, doctor
study chair · Zhongda Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion